NCT07105059

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Teclistamab	After the priming, patients will start Teclistamab step up dosing. Mezigdomide will not be given during the Teclistamab step up. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
DRUG	Mezigdomide	Start with 14 days of Mezigdomide. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.

Timeline

• Start date: 2025-08-08
• Primary completion: 2028-08-08
• Completion: 2028-08-08
• First posted: 2025-08-05
• Last updated: 2026-02-09

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study